IFNG and neoplasm: Studies have shown that CD3 bispecific antibodies can target and bind tumor cells, recruit and activate T cells at tumor sites to specifically kill tumor cells, change the immune microenvironment of tumors, release cytokines such as IL-2, TNF-α, and IFN-γ, and activate other immune cells to exert the body’s own immune function [33,34].